Capability

Biologics Drug Product CDMOs

Compare CDMOs specializing in biologics drug product formulation, aseptic fill-finish, and packaging for vials, syringes, and autoinjectors.

3 companies listed

About Biologics Drug Product Manufacturing

Biologics drug product (DP) manufacturing transforms the purified drug substance into the final formulated, filled, and packaged product. This includes formulation optimization (excipient selection, concentration, pH, surfactant), sterile filtration, aseptic filling into primary containers, optional lyophilization, visual inspection, labeling, and secondary packaging.

Protein stability drives formulation complexity. Biologics are susceptible to aggregation, deamidation, oxidation, and fragmentation. The formulation must protect against these degradation pathways throughout the shelf life. CDMOs need scientists experienced in protein characterization and stability-indicating assay development.

Companies (3)

PharmaPharma Ltd.

United Kingdom

PharmaPharma Ltd. is a leading contract development and manufacturing organization headquartered in United Kingdom. We specialize in Contract Research Organization (CRO), Fill/Finish with state-of-the-art facilities serving clients globally.

Cytotoxic / ADC HandlingHigh-Potency APISterile Fill/Finish

Standard Chem. & Pharm. Co., Ltd.

Taiwan

Standard Chem. & Pharm. Co., Ltd. is a pharmaceutical CDMO offering comprehensive services.

Cytotoxic / ADC HandlingHigh-Potency APISterile Fill/Finish

Frequently Asked Questions

What container formats are used for biologic drug products?+

The primary containers for biologics include: glass vials (most common, available in 2-50mL sizes), pre-filled syringes (growing rapidly for self-administered products), cartridges (for pen injector devices), and IV bags (for hospital-administered infusions). Container selection depends on the route of administration, dose volume, and whether the product is self-administered or healthcare professional-administered.

Why is visual inspection important for biologics?+

Biologic drug products must be free of visible particulates, which could indicate protein aggregation, glass delamination, or foreign contamination. 100% visual inspection (manual or automated) is required by regulatory agencies. Automated inspection systems use high-speed cameras and algorithms to detect particles, container defects, and fill volume variations. CDMOs should demonstrate validated inspection processes with defined sensitivity.

Related Categories

Biologics Drug Substance CDMOs Fill-Finish CDMOs Lyophilization CDMOs Biologics CDMOs CDMOs in North America

Need help finding the right CDMO?

Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.

Try AI Matchmaker Create Free Account